Dyax named ‘Top Place to Work’

Wednesday, November 18, 2015

Dyax, a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, has been named one of the Top Places to Work in Massachusetts by The Boston Globe for the second year in a row.

[Read More]

Shire to acquire Dyax for $5.9B

Monday, November 2, 2015

Dublin-based Shire has announced it will acquire Dyax for $37.30 in cash per Dyax share, for aggregate upfront consideration of about $5.9 billion. Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4 in cash per Dyax share upon approval of DX-2930 in HAE, representing a potential additional $646 million in aggregate contingent consideration.

[Read More]